Journal articleMol Cancer2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
- Journal
- Mol Cancer
- Published
- 13 March 2025
- Citations
- 27
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try